July 2023

Coverage of research presented by Strategic Alliance Partners: OneOncology, Florida Cancer Specialists & Research Institute, and The US Oncology Network.

Coverage of ASCO sessions and posters that addressed lessons from the Oncology Care Model and concerns about the Enhancing Oncology Model, which launched shortly after the annual meeting ended.

Coverage of sessions on disparities in access to clinical trials and cancer screening, as well as relationships each to outcomes. A joint session presented by ASCO and the European Society for Medical Oncology (ESMO) highlighted progress and lingering gaps in lung and colorectal screening.

Results included those for several bispecifics, used as monotherapy and in combination, including early results for 2 bispecifics used together.

Presentation of the COMMANDS trial offered practice-changing results for luspatercept.

Results include a landmark study that involved seamless collaboration across adult and pediatric patient groups, leading to a highly diverse study population. Other coverage addresses access to novel therapies and what's coming in the pipeline, including CAR T-cell therapy with tyrosine kinase inhibitors.

Coverage of clinical trial results presented across a range of solid tumor cancers, including breast, ovarian, colorectal, and non-small cell lung cancer, among other types; as well as important findings in genomic testing.

Coverage of addresses by ASCO President Eric P. Winer, MD, and National Cancer Institute Director Monica M. Bertagnolli, MD, who is a former ASCO president.